Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RPRX
RPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RPRX News
Royalty Pharma Reports Strong Q1 Earnings Growth
4d ago
NASDAQ.COM
Royalty Pharma Q1 2026 Earnings Call Highlights
4d ago
seekingalpha
Royalty Pharma Reports Q1 Revenue Growth of 11.1% but Misses Expectations
5d ago
seekingalpha
Royalty Pharma to Announce Q1 Earnings on May 6
5d ago
seekingalpha
Royalty Pharma Launches Translational Medicine Prize
Apr 21 2026
Newsfilter
Royalty Pharma Announces Q2 2026 Dividend Payment
Apr 17 2026
Newsfilter
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
Mar 30 2026
seekingalpha
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
Mar 30 2026
NASDAQ.COM
Royalty Pharma Partners with Johnson & Johnson for $500 Million R&D Agreement
Mar 30 2026
Newsfilter
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
Mar 30 2026
moomoo
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Mar 30 2026
moomoo
VFLO Stock Price Analysis and ETF Dynamics
Mar 23 2026
NASDAQ.COM
Zymeworks Secures $250 Million Royalty Financing from Royalty Pharma
Mar 02 2026
NASDAQ.COM
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Newsfilter
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Yahoo Finance
Teva and Medincell's NDA for Long-Acting Olanzapine Accepted by FDA
Feb 21 2026
seekingalpha
Show More News
